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Abstract
Objective To examine the risk of neurological and autoimmune disorders
of special interest in people vaccinated against pandemic influenza A
(H1N1) with Pandemrix (GlaxoSmithKline, Middlesex, UK) compared
with unvaccinated people over 8-10 months.
Design Retrospective cohort study linking individualised data on
pandemic vaccinations to an inpatient and specialist database on
healthcare utilisation in Stockholm county for follow-up during and after
the pandemic period.
Setting Stockholm county, Sweden.
Population All people registered in Stockholm county on 1 October
2009 and who had lived in this region since 1 January 1998; 1 024 019
were vaccinated against H1N1 and 921 005 remained unvaccinated.
Main outcome measures Neurological and autoimmune diagnoses
according to the European Medicines Agency strategy for monitoring of
adverse events of special interest defined using ICD-10 codes for
Guillain-Barré syndrome, Bell’s palsy, multiple sclerosis, polyneuropathy,
anaesthesia or hypoaesthesia, paraesthesia, narcolepsy (added), and
autoimmune conditions such as rheumatoid arthritis, inflammatory bowel
disease, and type 1 diabetes; and short term mortality according to
vaccination status.
Results Excess risks among vaccinated compared with unvaccinated
people were of low magnitude for Bell’s palsy (hazard ratio 1.25, 95%
confidence interval 1.06 to 1.48) and paraesthesia (1.11, 1.00 to 1.23)
after adjustment for age, sex, socioeconomic status, and healthcare
utilisation. Risks for Guillain-Barré syndrome, multiple sclerosis, type 1
diabetes, and rheumatoid arthritis remained unchanged. The risks of
paraesthesia and inflammatory bowel disease among those vaccinated
in the early phase (within 45 days from 1 October 2009) of the vaccination
campaign were significantly increased; the risk being increased within
the first six weeks after vaccination. Those vaccinated in the early phase
were at a slightly reduced risk of death than those who were
unvaccinated (0.94, 0.91 to 0.98), whereas those vaccinated in the late
phase had an overall reduced mortality (0.68, 0.64 to 0.71). These
associations could be real or explained, partly or entirely, by residual
confounding.
Conclusions Results for the safety of Pandemrix over 8-10 months of
follow-up were reassuring —notably, no change in the risk for
Guillain-Barré syndrome, multiple sclerosis, type 1 diabetes, or
rheumatoid arthritis. Relative risks were significantly increased for Bell’s
palsy, paraesthesia, and inflammatory bowel disease after vaccination,
predominantly in the early phase of the vaccination campaign. Small
numbers of children and adolescents with narcolepsy precluded any
meaningful conclusions.
Introduction
In June 2009 the World Health Organization declared the new
influenzaofswineorigin,A(H1N1),apandemic.
1InSeptember
2009theEuropeanMedicinesAgencyauthorisedthreevaccines
2
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Research
RESEARCHthrough an expeditious procedure adapted for a pandemic
situation. Owing to the need for large quantities of vaccine,
WHO had encouraged the development of vaccines with
adjuvants.
3 Evidence from the development of H5N1 vaccines
indicated that adjuvants could reduce the amount of antigen
needed to provide an adequate immunological response and
reinforce the ability to provide longlasting protection.
4 5 Two
of the A (H1N1) pandemic vaccines, Pandemrix
(GlaxoSmithKline, Middlesex, UK) and Focetria (Novartis,
Basel, Switzerland), are based on novel adjuvants AS03 and
MF59, containing squalene.
One safety consideration is the suggested
autoimmunostimulating potential of such adjuvants.
6 7 Another
is the increased risk of neurological adverse events, such as the
Guillain-Barré syndrome. Previous studies have shown an
increased risk of Guillain-Barré syndrome after influenza
vaccination, with relative risks ranging from more than 7 in a
studyfrom1957toabout1.5instudiesfrom1976and1992-4.
8-10
Other neuroimmunological events such as Bell’s palsy have
also been linked to previous vaccination against influenza.
11 12
So far no formal studies have been published on adverse events
in people undergoing H1N1 vaccination with any of the three
vaccines used in the European Union. Available data are, with
one exception,
13 limited to case series or highly selected
populations with short follow-up or no control group.
14-16
Increased risks of narcolepsy in children and adolescents have
been recently reported in epidemiological studies carried out
by the Swedish Medical Products Agency and the Finnish
Institute of Health and Welfare.
17-19
A population based pandemic vaccination programme with
Pandemrix was carried out from October 2009 to March 2010
in Sweden (population 9.3 million). The national overall
coverage was about 60%. In the Stockholm population of some
two million inhabitants, data on exposure to Pandemrix
vaccination were linked through the personal identity number
20
to data on inpatient and specialist care to ascertain outcomes of
special interest according to the European Medicines Agency
strategy for monitoring pandemic vaccines.
21
Over a period of 8-10 months we examined the risk of
neurological and autoimmune disorders of special interest in
people vaccinated against pandemic H1N1 with Pandemrix
compared with those who remained unvaccinated.
Methods
The study population consisted of all people (vaccinated and
unvaccinated) registered in Stockholm county on 1 October
2009 and who had lived in the region since 1 January 1998 (to
enable characterisation of cohorts from data tracked in the
healthcare database before the pandemic period). The study
population comprised 1.98 million people, of whom 52.6% (1
024 019) had been vaccinated.
Exposure to Pandemrix
Before the pandemic vaccination campaign a web based
vaccination register, the Vaccinera, was established in
Stockholm county. Vaccinated people were registered
continually online. Data from Vaccinera included information
onthedatesforafirstandseconddoseofvaccine,batchnumber,
medicalcontraindicationsagainstvaccination(suchasallergies
and bleeding disorders), and chronic conditions defining high
risk patients. Healthcare institutions that participated in the
vaccination campaign were required to enter data in the
Vaccineraregister,whichalsoallowedthecountyadministration
tofollowvaccinecoverage.Toensurethatallvaccinationswere
registered in Vaccinera, reimbursements for vaccinations were
processed only when a record was completed and submitted
online.
In Sweden, H1N1 vaccinations were initially (from the start of
the campaign in mid-October 2009 and during the subsequent
oneandhalfmonths)targetedathealthcareworkersandgroups
considered to be at high risk of complications from
influenza—that is, children with multifunctional disorders;
pregnant women; patients with chronic heart or lung disease,
diabetes mellitus, chronic liver failure, chronic renal failure, or
immunosuppression; people with extreme obesity (body mass
index >40); and patients with neuromuscular disease affecting
breathing capacity. Data on diagnoses from primary care and
hospitals showed that an estimated 10% of the population had
a chronic condition putting them at risk.
22
Weconsideredpeoplewhoreceivedatleastonedoseofvaccine.
A potential effect of a second dose was not evaluated.
Outcomes and definitions
For the purposes of this study we defined the pandemic period
as starting on 1 October 2009. The vaccination campaign with
Pandemrix started in mid-October.
We linked individualised data on vaccination to data on
utilisation of inpatient and specialist healthcare in the common
healthcare registers for Stockholm County Council (the GVR)
from1January1998to31August2010.Thisdatabasecontains
informationonalladmissionstohospitalandvisitstospecialist
care in the county, such as dates, diagnoses (international
classification of diseases), responsible medical departments,
and length of hospital stay. Data in the healthcare database are
continuallytransferredtothehealthcareadministrationdatabase,
whereapatient’sidentitynumberisreplacedbyacodenumber.
23
We used the same key for coding for the Vaccinera database to
be able to link the two systems on an individual basis without
revealing the patient’s identity.
Neurological and autoimmune diagnoses
We selected neurological and autoimmune diagnoses for
follow-upinlinewiththeEuropeanMedicinesAgencystrategy
for monitoring the safety of pandemic vaccines,
21 defined
according to ICD-10 (international classification of diseases,
10th revision) codes for hospital admissions and visits to
specialistcare(seewebextraappendix).Neurologicaloutcomes
of special interest included Guillain-Barré syndrome, Bell’s
palsy, multiple sclerosis, polyneuropathy, anaesthesia or
hypoaesthesia, paraesthesia, narcolepsy, and autoimmune
conditions such as rheumatoid arthritis, inflammatory bowel
disease(ulcerativecolitis,Crohn’sdisease),andtype1diabetes.
Entering diagnoses into the county healthcare database is part
of the doctor’s routine diagnostic work and therefore depends
on patients seeking healthcare. We did not actively search for
adverse events during the study period.
We examined the risk of narcolepsy in the subgroup of people
born in 1990 or later, as case reports have suggested a link
between the condition and H1N1 vaccination in that age group.
Furthermore, we examined the association between H1N1
vaccinationandinsulindependentdiabetesinpeoplebornfrom
1990 onwards (onset at age ≤20 years) as a proxy for type 1
diabetes.
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RESEARCHPrevalent and incident disease
Prevalent disease was defined as having the selected ICD-10
diagnosis (see web extra appendix) registered in the healthcare
administration database from 1 January 1998 to 30 September
2009 (before the pandemic period).
Incident disease was defined as having the selected ICD-10
diagnosis included for the first time from 1 October 2009 to 31
August 2010 (during or after the pandemic period for
unvaccinated people and after a first vaccination for vaccinated
people).
Socioeconomic classification
We used the Stockholm mosaic classification as a proxy for
socioeconomic status.
24 This classification is based on 11
exclusive categories of living conditions and economic
situations—for example, being affluent and living in the inner
Stockholm city or living in a small house in the suburbs or
countryside.
Statistical analyses
All statistical analyses were carried out using SAS 9.2. We
carriedoutanalysesintwoparts.Firstly,weanalysedprevalent
disease at the start of the follow-up as a predictor for the
vaccination. Secondly, we analysed incident disease in relation
to history of the vaccination. In all analyses of incident disease
weexcludedprevalentcasesoftherespectiveanalyseddisease.
Disease history as a predictor for vaccination
At the start of the study we used conditional logistic regression
to analyse prevalent disease, with history of disease as the
outcome and vaccination status as a predictor. We divided the
vaccinated group into two categories of the vaccination
campaign: the early phase, defined by vaccination within 45
days of the 1 October 2009, and the late phase, defined by
vaccination after that period. The results are presented as
prevalenceoddsratioswith95%confidenceintervals,with0.05
considered as the level of statistical significance. We used
conditioning to adjust estimates for sex, age (five year birth
cohort), and socioeconomic status.
Risk of subsequent neurological and autoimmune
diseases
We had no formal statistical analysis plan for the risk analyses,
beyond the a priori chosen outcomes, choice of time scale, and
use of Cox’s regression analysis to assess the overall effects of
vaccination. The initial analyses comprised the overall
associationwithoutadjustmentforhealthcareutilisation,where
four of the selected outcomes showed a significant association
with vaccination. Owing to the a priori knowledge that risk
groups were prioritised for vaccination, we stratified the risk
estimates for vaccination in both the early and the late phases
of the campaign. We chose the cut-off point of 45 days to
includethefirstmonthofthecampaignintheearlyphase.After
thisstratificationwefoundthatthesignificantassociationswere
confined to those vaccinated in the early phase. Because risk
groups can be assumed to have easier access to hospital care,
which we used for assessing the outcomes, we further adjusted
theriskestimatesforutilisationofhealthcare.Wechosecalendar
time from 1 October 2009 as the time scale and we considered
vaccination as a time varying covariate. Calendar time was
chosen as the time scale for analysis to control for potential
seasonal effects in incidences of the outcomes under study. In
a second model we conditioned further on the number of
in-hospital admissions and visits to specialist care one year
before vaccination. The results are presented as hazard ratios
with95%confidenceintervals,with0.05consideredasthelevel
of statistical significance. We estimated the number of cases
attributabletovaccinationinthevaccinatedgroupasthenumber
of observed cases in the vaccinated group multiplied by
1−1/hazard ratio. We estimated the absolute excess risk among
vaccinated people as the number of cases attributable to
vaccination divided by the number of vaccinated people.
The hazard ratios related to vaccination were stratified on time
since vaccination and calendar time of vaccination. We used
six weeks as a cut-off point for stratification according to time
since vaccination. The early phase of the vaccination campaign
was defined by vaccination within 45 days of 1 October 2009
and the late phase by vaccination after that period. The
vaccinations started on 13 October (except for 10 people who
hadbeenvaccinatedearlier);thecut-offpointusedincludesthe
first 32 days of the vaccination campaign (43.6% of all
vaccinated people) in the early phase. To investigate whether
there was an acute effect of the vaccination (that is,
non-proportional hazards on the time scale time since
vaccination),weanalysedestimatesstratifiedaccordingtoboth
times (see table 4). We used likelihood ratio tests to determine
the interactions between calendar time of vaccination and time
since vaccination.
Post hoc analyses
In an attempt to further estimate the influence of underlying
comorbidity on health outcomes in patients undergoing H1N1
vaccination, we also estimated short term mortality according
to vaccination status.
Results
By 31 March 2010 virtually all vaccination activity had been
completed, with a cumulative 1 024 019 people vaccinated
(52.6%ofthestudypopulation;figure⇓).Inall,222388people,
of whom 66.4% received a second dose, were vaccinated
between the ages of six months and 12 years. Those belonging
to a high risk group were largely over-represented compared
with the total population during the first six weeks of the
campaign (mid-October to November 2009); 74% of all those
vaccinated in the first week and 30% in the sixth week. In a
second phase (from the beginning of December) the remainder
of the population was offered vaccination.
22
Table1⇓showsvaccinecoveragebysex,socioeconomicstatus,
andbirthcohort.Morewomenthanmenwerevaccinated(55.9%
v49.3%).Childrenandmiddleagedandolderpeopleweremore
often vaccinated than younger adults. Vaccine coverage was
greater in those of a higher socioeconomic status.
Prevalent disease at vaccination
Neurological and autoimmune disorders were more prevalent
in those vaccinated in the early phase of the campaign (first 45
days) than in the unvaccinated cohort (table 2⇓). No such
differenceswereseenforthosevaccinatedinthelatephase(>45
days) compared with the unvaccinated cohort, except for
inflammatory bowel disease (prevalence odds ratio 1.17, 95%
confidence interval 1.12 to 1.22). Those vaccinated in the late
phasehadalowerprevalenceofGuillain-Barrésyndrome(0.79,
0.67 to 0.95) and type 1 diabetes (0.77, 0.64 to 0.92, for those
born in 1990 and later). This pattern of morbidity is consistent
with the Swedish strategy to prioritise high risk groups in the
early phase of the campaign.
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RESEARCHRisk of selected, incident, neurological and
autoimmune diseases
Compared with the unvaccinated cohort the vaccinated cohort
showed positive associations with Bell’s palsy (hazard ratio
1.25, 95% confidence interval 1.06 to 1.48) and paraesthesia
(1.11,1.00to1.23),afteradjustmentforage,sex,socioeconomic
status,andutilisationofhealthcare(table3⇓).Thiscorresponds
toabsoluteexcessrisksinthevaccinatedpopulationof8.4cases
per 100 000 vaccinated person years for Bell’s palsy (95%
confidenceinterval2.3to13.4)and9.2casesper100000person
years for paraesthesia (0 to 17.5). The small number of cases
ofnarcolepsyobservedamongpeopleaged20yearsandyounger
(sixinthevaccinatedcohortandtwointheunvaccinatedcohort)
preclude any meaningful interpretation.
The risks of neurological and autoimmune diseases after
vaccination were further examined in relation to the early and
latephasesofthevaccinationcampaign(table4).Intheanalyses
without adjustment for healthcare utilisation, the difference in
risk between those vaccinated in the early and late phases was
significant for paraesthesia, inflammatory bowel disease,
rheumatoid arthritis, anaesthesia or hypoaesthesia, and Bell’s
palsy. However, after adjustment for healthcare utilisation this
difference between the two phases remained significant only
for paraesthesia (P=0.003) and inflammatory bowel disease
(P=0.04).
Early vaccinations (≤45 days) were associated with a
significantly increased risk for Bell’s palsy (hazard ratio 1.34,
95% confidence interval 1.11 to 1.64), paraesthesia (1.25, 1.10
to 1.41), and inflammatory bowel disease (1.25, 1.04 to 1.50;
table 3) after adjustment for healthcare utilisation in addition
to age, sex, and socioeconomic status. These risk estimates
became lower after adjustment for healthcare utilisation before
the pandemic period, reflecting outcomes in people within risk
groups. In this subcohort the increased risk was not evident for
Guillain-Barré syndrome, multiple sclerosis, type 1 diabetes,
or rheumatoid arthritis. In the subcohort of people vaccinated
inthelatephaseofthecampaign,noneoftheriskestimateswas
statistically significantly increased for the vaccinated cohort
compared with unvaccinated cohort.
In analyses stratified according to time since first vaccination
(table4⇓)theexcessincidencesofBell’spalsyandparaesthesia
were most pronounced among those vaccinated in the early
phase (1.74, 1.16 to 2.59) and during the six weeks after
vaccination(1.60,1.25to2.05).Thesehazardratioscorrespond
to absolute excess risks of 30 (95% confidence interval 10 to
44) and 65 (1.5 to 89) cases per 100 000 vaccinated person
years,respectively.SignificantbutsmallerexcessrisksofBell’s
palsy and paraesthesia more than six weeks after vaccination
were also observed among those vaccinated in the early phase.
The excess risk of inflammatory bowel disease among those
vaccinated in the early phase was only observed more than six
weeks after vaccination. The overall absence of an excess risk
for type 1 diabetes among people aged less than 20 years was
consistentinbothriskwindows(withinandmorethansixweeks
from vaccination) and among people vaccinated in the early
and late phases. However, formal tests to determine whether
risks further differed between within and more than six weeks
from vaccination were only statistically significant for
paraesthesia (P=0.005).
In a post hoc analysis of the risk of death (table 5⇓), those who
were vaccinated in the early phase were at a slightly reduced
risk of death compared with those who remained unvaccinated
after adjustment for earlier healthcare utilisation in addition to
age, sex, and socioeconomic status (hazard ratio 0.94, 95%
confidenceinterval0.91to0.98).Incontrast,peopleundergoing
vaccination more than 45 days after study entry had a lower
overall mortality than those who remained unvaccinated, also
after adjustment for previous healthcare utilisation in addition
to age, sex, and socioeconomic status (0.68, 0.64 to 0.71).
Discussion
Among the more than one million people vaccinated with the
squalene adjuvanted Pandemrix vaccine in Stockholm county
(the only vaccine used in Sweden against pandemic H1N1), the
risks of Bell’s palsy and paraesthesia were increased. Excess
risks for Bell’s palsy, paraesthesia, and inflammatory bowel
disease were, however, observed only among those vaccinated
intheearlyphaseofthevaccinationcampaign(≤45days),when
high risk groups predominated. In contrast, among people
vaccinated after the first 45 days of the campaign, representing
more closely the general population, we found no statistically
significant associations between vaccination and autoimmune
or neurological diseases. Change in the risks for Guillain-Barré
syndrome, multiple sclerosis, diabetes, or rheumatoid arthritis
was not evident in any of the analyses. As to the risk of
narcolepsyinadolescentsandchildren,smallnumbersprecluded
any meaningful conclusions.
People vaccinated in the first 45 days consistently more often
hadapreviousdiagnosisofneurologicalorautoimmunedisease
than those who remained unvaccinated. Earlier neurological
and autoimmune disease was therefore a strong predictor for
vaccination in the first 45 days—for example, those with type
1 diabetes were at a sixfold increased risk of being vaccinated
early.Togetherwiththehighproportionreportedtohaveahigh
riskconditionaccordingtotheVaccineradatabase,thissuggests
that the national recommendation to vaccinate high risk groups
first was followed. Earlier comorbidity could explain some of
the excess risks seen in those vaccinated early. Even if hazard
ratios decreased for almost all outcomes (for example, Bell’s
palsy from 1.49 to 1.34; inflammatory bowel disease from 1.43
to 1.25, and paraesthesia from 1.43 to 1.25) after adjustment
for the number of hospital admissions and visits to specialist
care, some residual confounding may still exist. These small
excessrisksmaybepartlyorentirelyexplainedbyotherfactors
that were not captured by a crude measure of healthcare
utilisation. Nevertheless, if true, these hazard ratios would
translate into low absolute risks.
In contrast, those vaccinated in the later part of the campaign
hadasimilardistributionofearlierneurologicalandautoimmune
disease (with the exception of a small increase in previous
inflammatory bowel disease) as unvaccinated people.
Furthermore, those in this subcohort were at no statistically
increased risk of any of our analysed outcomes, suggesting that
in a general population vaccination with Pandemrix is unlikely
to lead to an important effect on the risk for neurological or
autoimmune diseases (not accounting for risk of narcolepsy).
However, mortality, even after adjustment for previous
healthcareutilisationinadditiontoage,sex,andsocioeconomic
status, was lower in this vaccinated subcohort than in the
unvaccinated cohort. This may reflect a healthy selection of
people for those vaccinated and that our risk estimates for
neurologicalandautoimmuneoutcomesmaybeunderestimates.
Comparisons with previous studies and
findings
Most available data on the safety of A (H1N1) pandemic
vaccines—with Pandemrix being the most commonly used
vaccine in the European Union (estimated use in some 30
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RESEARCHmillion)—are based on reports of spontaneous adverse drug
events to national regulatory agencies. Such data have been
generally reassuring during and after the pandemic period.
However, an increased risk of narcolepsy in children and
adolescents,withincreasedrelativerisksrangingfromfourfold
to ninefold, have been recently reported from authorities in
Sweden and Finland,
17-19 leading to regulatory action by the
European drug regulatory body, the European Medicines
Agency, in July 2011 to restrict the use of Pandemrix
vaccinations.
25 Regarding other outcomes, some pertinent
conclusions can be drawn from published studies on the safety
of influenza vaccinations in general.
Althoughpreviousstudieshaveproducedconflictingresultson
an association between Guillain-Barré syndrome and influenza
vaccination,
8-10 26 two larger studies reported no positive
association.
27 28 In our study we found no association between
vaccination with an adjuvanted H1N1 vaccine and
Guillain-Barré syndrome. Our findings are consistent with a
Chinese study of a non-adjuvanted pandemic vaccine
14 and add
tothatstudybecausewewereabletoestimatehazardratiosand
our study population was not restricted to previously healthy
people.
Although a large number of studies have examined the
association between various types of vaccinations and type 1
diabetes,
29-32nonehasshownanassociation.
33Toourknowledge
no studies have been carried out on influenza vaccinations (for
example, using squalene adjuvanted vaccines) and risk of type
1diabetes.InourstudywefoundnoassociationbetweenH1N1
vaccination and type 1 diabetes in the age group where most
cases of the disease occur (those born in 1990 and later).
Theexcessriskforparaesthesiamayconstitutealocalsymptom
(for example, pain, redness, swelling, tingling) at the injection
sitefromtheH1N1vaccination.Theexcessriskofparaesthesia
was only of borderline significance (95% confidence interval
1.00 to 1.23) and absent in patients undergoing vaccination in
the late phase.
We cannot explain the small increase in risk for Bell’s palsy
seen in this study. Potential causes include viral infection and
pregnancy, neither of which could be dealt with using the data
in our analyses. The absolute risk of Bell’s palsy was low, 6.4
cases per 100 000 vaccinated population.
Safety considerations of European Medicines
Agency for adjuvanted pandemic A (H1N1)
vaccines
The pandemic vaccines were developed by using a prototype
vaccine that contained the H5N1 antigen and an adjuvant—for
Pandemrix, squalene combined with DL-α-tocopherol. This
mock-up vaccine was recommended for approval in 2008 by
the European Medicines Agency, based on data on efficacy
(antibodyresponse)andsafetyinsome5000peopleaged18-65
years. After approval of the final vaccine in September 2009, a
trial was carried out in 300 children aged 3-12 years. Thus at
the time of release on to the market in October 2009 the safety
experience of Pandemrix was deemed to be limited. The
EuropeanMedicinesAgencyencouragedastrategyforenhanced
pharmacovigilance, implying stimulated reporting of
spontaneous adverse drug reactions and the start of
epidemiological studies. During and after the pandemic
vaccinationperiodinSweden,reportsonadversedrugreactions
for Pandemrix were generally reassuring but produced a new
signal for allergic reactions. In the autumn of 2010 an
unexpectedly large number of reports on narcolepsy in
adolescents and children was noted by the Medical Products
AgencyinSweden(asinFinland).
18Subsequentepidemiological
studies in Sweden and Finland reported several-fold increased
risks of narcolepsy in children and adolescents.
17-19 Our trial is
the first data based study on an array of neurological and
autoimmune safety outcomes for one of the pandemic vaccines
used in the European Union.
Strengths and limitations of the study
Throughthevaccinationregister(Vaccinera)ourstudycovered
allvaccinatedpeopleinStockholmcounty.Theuniquepersonal
identitynumberenabledustoascertaindataonearlierutilisation
ofhealthcareaswellastoadjustforsex,age,andsocioeconomic
status. We used ICD codes assigned by doctors to identify
neurological and autoimmune diseases recorded in the
Stockholm healthcare database. Our large number of study
participants allowed for precise risk estimates for many of the
outcomes.Forinstance,forararediseasesuchasGuillain-Barré
syndromewecouldruleoutahazardratioof1.7orgreater(table
3). Through data on healthcare utilisation before the pandemic
period we could also explain at least part of the excess risks
seen in those vaccinated early against H1N1.
Our study has some limitations that may have influenced our
risk estimates. The neurological and autoimmune diseases
studied were diagnosed and entered in the healthcare database
as part of the clinical routine in the county and thus depended
on patients seeking healthcare because of their greater
availability for specialist care. We also lacked detailed data on
covariates, with the possibility for residual confounding. For
instance, the lower mortality in those vaccinated in the late
phase was not explained through adjustment for earlier
healthcare utilisation. If people in this subcohort are healthier
thanthegeneralpopulationourstudymayhaveunderestimated
the risk of adverse effects in those who were vaccinated. Two
circumstances argue against our hazard ratios being
underestimates. Firstly, neurological and autoimmune diseases
were similar in people of this subcohort undergoing late
vaccination and in the unvaccinated cohort. Secondly, as
cardiovascular disease and cancer are by far the most common
causes of death in Sweden, the lower mortality in those
vaccinated should be sought in low levels of smoking or a low
body mass index. However, neither smoking nor high body
massindexisamajorriskfactorforneurologicalorautoimmune
diseases, and therefore a skewed distribution of these
characteristics is unlikely to hide a true association between
H1N1 vaccination and our outcomes.
Furthermore,highriskgroupswereover-representedintheearly
phase of the vaccination campaign (as shown by a higher
prevalence at the start of follow-up for most of the selected
outcome diagnoses). This implies that this subgroup is not
obviously comparable with the unvaccinated subgroup, thus
potentially leading to selection bias. Since we have access only
to data on visits to specialist care and hospital admissions,
surveillance bias is also a concern—namely, that vaccinated
patients may have better access to specialist care than
unvaccinated patients, especially those belonging to medical
risk groups. To some extent we controlled for both selection
biasandsurveillancebiasbyadjustmentforhealthcareutilisation
beforethestartoffollow-up,whichgenerallyresultedinreduced
risk estimates. Residual confounding is, however, still a
possibility.
Overall, 90% of the vaccinated people had a follow-up time
ranging from 256 days to 315 days. For certain conditions
requiring a long period of investigation or if an adverse effect
of the vaccination is delayed, the follow-up time may be too
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RESEARCHshort to reveal the full effect, which would result in an
underestimation of the true effect. The influence of chance is a
problemwhenevaluatingmultipleendpointsdividedaccording
to two temporal aspects. Furthermore, the power of our study
to detect change of risk for rare outcomes such as narcolepsy
was insufficient.
Conclusions and implications
Basedondatafromfollow-upduring8-10monthsamongmore
than one million people vaccinated with Pandemrix and 900
000 unvaccinated people in the entire population of Stockholm
county, we found mostly reassuring results, notably for
Guillain-Barré syndrome, multiple sclerosis, type 1 diabetes,
and rheumatoid arthritis. Although we found small excess risks
(ranging from 1.25 to 1.34) for some neurological and
autoimmune diseases after vaccination, such as Bell’s palsy,
paraesthesia, and inflammatory bowel disease, these were only
seen in those among high risk groups targeted for early
vaccination and who were likely to have earlier comorbidity,
which could partly or entirely have explained the findings. As
to the association between vaccination with Pandemrix and
narcolepsyinadolescentsandchildren,smallnumbersprecluded
meaningful results.
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RESEARCHWhat is already known on this topic
Studies are lacking on adverse events (except for narcolepsy) with any of the three vaccines used in the European Union against H1N1
during the pandemic period
Available data are limited to case series or highly selected populations with short follow-up or no control group
What this study adds
Excess risks for Bell’s palsy, paraesthesia, and inflammatory bowel disease after H1N1 vaccination with adjuvanted Pandemrix in
Sweden were small but significant among more than one million vaccinated, but only in high risk groups targeted for early vaccination
and who were likely to have earlier comorbidity
The risk of Guillain-Barré syndrome, multiple sclerosis, type 1 diabetes, and rheumatoid arthritis remained unchanged
Small numbers of children and adolescents with narcolepsy precluded any meaningful conclusions
Tables
Table 1| Numbers and percentage proportions of vaccine coverage by sex, socioeconomic status, birth cohorts, and healthcare utilisation
one year before pandemic period, in Stockholm county, Sweden
Coverage (%)
Vaccination status
Category Vaccinated Unvaccinated
52.6 1 024 019 921 005 All
55.9 550 856 434 727 Women
49.3 473 163 486 278 Men
Socioeconomic status*:
54.6 109 179 90 819 Affluent, inner city
51.7 92 568 86 379 Inner city
50.8 128 330 124 323 Mixed, near city
44.3 18 852 23 684 Young, near suburb
47.2 108 221 120 958 Older, near suburb
49.6 51 208 52 074 Poor, suburb, apartment
39.7 98 832 149 956 Multicultural suburb
63.8 247 888 140 457 Affluent, near suburb
59.3 70 022 47 963 Own house, suburb
57.1 48 666 36 520 Small house, suburb
51.2 50 253 47 872 Countryside
Birth year cohort:
42.0 174 240 1900-9
53.8 8249 7075 1910-19
59.9 110 031 73 596 1920-39
56.1 120 071 93 806 1940-9
48.2 392 329 421 872 1950-79
35.4 47 332 86 234 1980-4
27.7 31 871 83 127 1985-9
52.3 64 814 59 117 1990-4
78.8 81 822 22 074 1995-9
78.1 89 239 24 984 2000-4
61.5 78 087 48 879 2005-1 Oct 2009
No of hospital admissions:
52.1 928 972 854 064 None
58.5 66 601 47 199 1
58.5 15 878 11 239 2
59.6 12 568 8503 ≥3
No of ambulatory care visits to hospital
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RESEARCHTable 1 (continued)
Coverage (%)
Vaccination status
Category Vaccinated Unvaccinated
49.9 596 869 599 097 None
55.4 154 379 124 429 1
56.8 81 793 62 181 2
57.5 50 119 37 035 3
58.3 33 038 23 659 4
59.1 107 821 74 605 ≥5
*Stockholm mosaic classification.
24
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RESEARCHTable 2| Associations of defined prevalent diseases with vaccination status (vaccinated versus unvaccinated), in subcohorts vaccinated
in early and late phases of H1N1 vaccination campaign in Stockholm county, Sweden
Prevalence odds ratios (95% CI) No Diseases and vaccination status
Neurological diseases
Bell’s palsy
1.00 (reference) 3236 Unvaccinated
1.26 (1.19 to 1.34) 1998 ≤45 days
1.01 (0.95 to 1.08) 1816 >45 days
Guillain-Barré syndrome:
1.00 (reference) 408 Unvaccinated
1.29 (1.11 to 1.50) 322 ≤45 days
0.79 (0.67 to 0.95) 188 >45 days
Multiple sclerosis:
1.00 (reference) 1275 Unvaccinated
2.97 (2.76 to 3.20) 1866 ≤45 days
0.92 (0.83 to 1.01) 654 >45 days
Anaesthesia or hypoaesthesia:
1.00 (reference) 991 Unvaccinated
1.40 (1.26 to 1.55) 671 ≤45 days
0.92 (0.82 to 1.02) 504 >45 days
Paraesthesia:
1.00 (reference) 5436 Unvaccinated
1.36 (1.30 to 1.42) 3605 ≤45 days
1.01 (0.97 to 1.06) 3005 >45 days
Polyneuropathy:
1.00 (reference) 1559 Unvaccinated
1.46 (1.36 to 1.57) 1556 ≤45 days
0.95 (0.88 to 1.04) 833 >45 days
Narcolepsy:
1.00 (reference) 86 Unvaccinated
1.35 (0.96 to 1.90) 61 ≤45 days
1.19 (0.84 to 1.68) 57 >45 days
Narcolepsy (aged ≤20 years):
1.00 (reference) 1 Unvaccinated
3.53 (0.31 to 39.8) 3 ≤45 days
2.69 (0.25 to 28.5) 3 >45 days
Autoimmune diseases
Rheumatoid arthritis:
1.00 (reference) 4861 Unvaccinated
2.03 (1.95 to 2.11) 5894 ≤45 days
0.94 (0.89 to 0.98) 2695 >45 days
Inflammatory bowel disease:
1.00 (reference) 6058 Unvaccinated
1.79 (1.72 to 1.86) 4946 ≤45 days
1.17 (1.12 to 1.22) 3838 >45 days
Type 1 diabetes*:
1.00 (reference) 268 Unvaccinated
6.17 (5.36 to 7.10) 1086 ≤45 days
0.77 (0.64 to 0.92) 219 >45 days
*Population born 1990 or later.
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RESEARCHTable 3| Risk of selected neurological and autoimmune diseases in vaccinated versus unvaccinated cohort and in subcohorts vaccinated
in early and late phases of H1N1 vaccination campaign in Stockholm county, Sweden
Hazard ratio (95% CI)*
Diseases and vaccination status Model 2 Model 1
Neurological diseases
Bell’s palsy:
1.25 (1.06 to 1.48) 1.35 (1.14 to 1.59) All vaccinated
1.34 (1.11 to 1.64) 1.49 (1.23 to 1.81) ≤45 days
1.16 (0.94 to 1.43) 1.19 (0.97 to 1.47) >45 days
Guillain-Barré syndrome:
1.07 (0.66 to 1.74) 1.27 (0.79 to 2.06) All vaccinated
1.08 (0.62 to 1.87) 1.40 (0.81 to 2.42) ≤45 days
1.07 (0.58 to 1.99) 1.13 (0.61 to 2.09) >45 days
Multiple sclerosis:
0.93 (0.68 to 1.26) 0.99 (0.73 to 1.35) All vaccinated
1.04 (0.72 to 1.48) 1.17 (0.82 to 1.66) ≤45 days
0.80 (0.54 to 1.20) 0.81 (0.54 to 1.21) >45 days
Anaesthesia or hypoaesthesia:
1.05 (0.77 to 1.43) 1.18 (0.87 to 1.61) All vaccinated
1.23 (0.86 to 1.74) 1.50 (1.06 to 2.12) ≤45 days
0.84 (0.56 to 1.27) 0.86 (0.57 to 1.30) >45 days
Paraesthesia:
1.11 (1.00 to 1.23) 1.20 (1.08 to 1.33) All vaccinated
1.25 (1.10 to 1.41) 1.43 (1.27 to 1.61) ≤45 days
0.94 (0.82 to 1.09) 0.96 (0.83 to 1.10) >45 days
Polyneuropathy:
1.11 (0.92 to 1.32) 1.33 (1.11 to 1.59) All vaccinated
1.09 (0.89 to 1.33) 1.40 (1.15 to 1.71) ≤45 days
1.14 (0.90 to 1.44) 1.22 (0.97 to 1.53) >45 days
Narcolepsy:
1.25 (0.47 to 3.30) 1.45 (0.56 to 3.75) All vaccinated
1.38 (0.46 to 4.17) 1.82 (0.63 to 5.21) ≤45 days
1.12 (0.34 to 3.66) 1.10 (0.34 to 3.59) >45 days
Narcolepsy (aged ≤20 years):
1.54 (0.30 to 8.01) 1.54 (0.30 to 7.89) All vaccinated
0.58 (0.05 to 6.69) 0.67 (0.06 to 7.70) ≤45 days
2.21 (0.41 to 11.8) 2.06 (0.38 to 11.0) >45 days
Autoimmune diseases
Rheumatoid arthritis:
0.94 (0.81 to 1.09) 1.03 (0.89 to 1.19) All vaccinated
1.01 (0.86 to 1.20) 1.17 (0.99 to 1.38) ≤45 days
0.84 (0.69 to 1.02) 0.86 (0.71 to 1.04) >45 days
Inflammatory bowel disease:
1.13 (0.97 to 1.32) 1.22 (1.04 to 1.42) All vaccinated
1.25 (1.04 to 1.50) 1.43 (1.20 to 1.71) ≤45 days
1.00 (0.82 to 1.22) 1.01 (0.83 to 1.23) >45 days
Type 1 diabetes†:
0.99 (0.67 to 1.47) 1.03 (0.70 to 1.53) All vaccinated
1.13 (0.72 to 1.78) 1.21 (0.77 to 1.89) ≤45 days
0.88 (0.57 to 1.38) 0.91 (0.59 to 1.41) >45 days
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RESEARCHTable 3 (continued)
Hazard ratio (95% CI)*
Diseases and vaccination status Model 2 Model 1
Both models were adjusted for age, sex, and socioeconomic status. Model 2 was further adjusted for healthcare consumption (number of hospital admissions and
visits to specialist care one year before pandemic period).
*Cox’s regression analyses.
†Population born 1990 or later.
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RESEARCHTable 4| Number and risk of neurological or autoimmune diseases among vaccinated cohort, stratified according to time since vaccination
(≤6 weeks and >6 weeks) and vaccination in early and late phases of H1N1 vaccination campaign in Stockholm county, Sweden
>6 weeks after vaccination ≤6 weeks after vaccination
Outcome
Late phase Early phase Late phase Early phase
Hazard ratio* (95%
CI)
No of
events
Hazard ratio* (95%
CI)
No of
events
Hazard ratio* (95%
CI)
No of
events
Hazard ratio* (95%
CI)
No of
events
Neurological
diseases:
1.16 (0.92 to 1.45) 130 1.26 (1.01 to 1.57) 145 1.02 (0.64 to 1.63) 21 1.74 (1.16 to 2.59) 37 Bell’s palsy
0.92 (0.45 to 1.89) 13 1.18 (0.64 to 2.17) 20 1.92 (0.68 to 5.40) 3 0.72 (0.19 to 2.66) 3 Guillain-Barré
syndrome
0.71 (0.45 to 1.12) 26 0.95 (0.63 to 1.44) 36 1.17 (0.53 to 2.57) 8 1.35 (0.68 to 2.67) 12 Multiple sclerosis
0.79 (0.50 to 1.24) 29 1.15 (0.78 to 1.69) 50 1.04 (0.43 to 2.55) 7 1.61 (0.77 to 3.39) 8 Anaesthesia or
hypoaesthesia
0.87 (0.75 to 1.02) 245 1.17 (1.02 to 1.34) 360 1.23 (0.91 to 1.65) 55 1.60 (1.25 to 2.05) 90 Paraesthesia
1.01 (0.77 to 1.31) 90 1.07 (0.86 to 1.34) 156 1.79 (1.16 to 2.77) 28 1.13 (0.75 to 1.70) 33 Polyneuropathy
1.42 (0.40 to 5.08) 5 1.57 (0.45 to 5.50) 6 — 0 0.98 (0.10 to 9.67) 1 Narcolepsy
2.25 (0.42 to 12.1) 5 0.58 (0.05 to 6.72) 1 — 0 — 0 Narcolepsy (age
≤20 years)
Autoimmune
diseases:
0.84 (0.68 to 1.04) 142 1.00 (0.83 to 1.20) 212 0.82 (0.52 to 1.28) 22 1.08 (0.74 to 1.57) 40 Rheumatoid arthritis
1.01 (0.82 to 1.25) 130 1.29 (1.06 to 1.58) 168 1.00 (0.65 to 1.54) 27 1.10 (0.74 to 1.63) 35 Inflammatory bowel
disease
0.85 (0.52 to 1.38) 39 1.18 (0.72 to 1.94) 37 1.18 (0.47 to 2.96) 7 0.89 (0.31 to 2.52) 6 Type 1 diabetes†
*Adjusted for age, sex, socioeconomic status, and healthcare utilisation one year before start of follow-up.
†Population born 1990 or later.
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RESEARCHTable 5| Risk of death from any cause in vaccinated versus unvaccinated individuals in subcohorts vaccinated in early and late phases of
H1N1 vaccination campaign in Stockholm county, Sweden
Hazard ratio (95% CI)*
No of deaths No of people Vaccination status Model 2 Model 1
0.85 (0.82 to 0.89) 0.95 (0.92 to 0.99) 6605 1 024 019 All vaccinated
0.94 (0.91 to 0.98) 1.12 (1.08 to 1.16) 4881 446 770 ≤45 days
0.68 (0.64 to 0.71) 0.67 (0.63 to 0.70) 1724 577 249 >45 days
Both models were adjusted for age, sex, and socioeconomic status. Model 2 was further adjusted for healthcare consumption (number of hospital admissions and
visits to specialist care one year before pandemic period).
*Cox’s regression analysis.
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RESEARCHFigure
Cumulative numbers of people vaccinated against A (H1N1) influenza in Stockholm county, Sweden, October 2009 (week
42) to March 2010 (week 13)
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